Amy Horton Sells 830 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) CAO Amy Horton sold 830 shares of the firm’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $35.69, for a total transaction of $29,622.70. Following the transaction, the chief accounting officer directly owned 127,497 shares of the company’s stock, valued at $4,550,367.93. The trade was a 0.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Amy Horton also recently made the following trade(s):

• On Monday, February 23rd, Amy Horton sold 1,731 shares of Artivion stock. The shares were sold at an average price of $37.59, for a total transaction of $65,068.29.
• On Monday, December 8th, Amy Horton sold 4,572 shares of Artivion stock. The stock was sold at an average price of $44.42, for a total value of $203,088.24.

Artivion Stock Performance

NYSE AORT opened at $38.14 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $48.25. The stock has a market capitalization of $1.83 billion, a PE ratio of 190.71 and a beta of 1.59. The business has a 50 day simple moving average of $42.09 and a two-hundred day simple moving average of $43.05.

Artivion (NYSE:AORT) last announced its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. The business’s revenue for the quarter was up 19.2% compared to the same quarter last year. On average, research analysts predict that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Canaccord Genuity Group cut their price target on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Oppenheimer restated an “outperform” rating and set a $50.00 target price on shares of Artivion in a research note on Friday, November 7th. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 price target on shares of Artivion in a research note on Monday, February 2nd. Finally, Citizens Jmp raised their price target on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.97.

Hedge Funds Weigh In On Artivion

Institutional investors have recently modified their holdings of the stock. Royal Bank of Canada lifted its holdings in shares of Artivion by 107.0% in the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock valued at $952,000 after buying an additional 20,010 shares during the period. AQR Capital Management LLC raised its position in Artivion by 8.8% during the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after acquiring an additional 2,823 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Artivion by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after acquiring an additional 1,032 shares in the last quarter. Oppenheimer Asset Management Inc. acquired a new position in Artivion in the second quarter valued at approximately $669,000. Finally, Envestnet Asset Management Inc. boosted its position in Artivion by 364.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 52,871 shares of the company’s stock worth $1,644,000 after purchasing an additional 41,487 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Key Stories Impacting Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q4 results topped expectations — revenue grew ~19% year‑over‑year and EPS beat consensus, supporting revenue momentum and margin recovery; this helps justify the current rally. Earnings & Company Page
• Positive Sentiment: Short interest fell ~15.4% in February to ~1.39M shares (~3.2% of float); lower short exposure reduces one source of downside selling and can make up‑moves easier to sustain. Short Interest/Insider Page
• Positive Sentiment: Institutional investors have increased or initiated positions in recent quarters (multiple funds cited), indicating professional conviction that could support longer‑term demand. Institutional Holdings
• Neutral Sentiment: Analyst coverage is mixed — consensus is a “Moderate Buy” with an average target near $49, but some shops have trimmed targets or moved to Hold, reflecting divergent views on near‑term upside. Analyst Notes
• Negative Sentiment: Large, broad insider selling across Feb. 23–24 (CEO James P. Mackin, EVP Lance Berry, SVPs and CAO made sizable open‑market disposals). While filings suggest open‑market liquidity/scheduled sales rather than insider panic, the scale and breadth can create short‑term selling pressure and investor unease. SEC filings: CEO Form 4 and related officer filings. CEO Form 4 EVP Form 4

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.